CN104066719B - 用作mogat-2抑制剂的苄基磺酰胺衍生物 - Google Patents

用作mogat-2抑制剂的苄基磺酰胺衍生物 Download PDF

Info

Publication number
CN104066719B
CN104066719B CN201380007085.XA CN201380007085A CN104066719B CN 104066719 B CN104066719 B CN 104066719B CN 201380007085 A CN201380007085 A CN 201380007085A CN 104066719 B CN104066719 B CN 104066719B
Authority
CN
China
Prior art keywords
compound
och
mmol
mogat
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380007085.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104066719A (zh
Inventor
M.C.费尔南德斯
M.R.冈萨雷斯-加西亚
L.A.普菲菲尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47148691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104066719(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN104066719A publication Critical patent/CN104066719A/zh
Application granted granted Critical
Publication of CN104066719B publication Critical patent/CN104066719B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201380007085.XA 2012-01-31 2013-01-24 用作mogat-2抑制剂的苄基磺酰胺衍生物 Active CN104066719B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261592717P 2012-01-31 2012-01-31
US61/592717 2012-01-31
US61/592,717 2012-01-31
EP12382432.8 2012-11-06
EP12382432 2012-11-06
PCT/US2013/022870 WO2013116075A1 (en) 2012-01-31 2013-01-24 Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors

Publications (2)

Publication Number Publication Date
CN104066719A CN104066719A (zh) 2014-09-24
CN104066719B true CN104066719B (zh) 2016-08-24

Family

ID=47148691

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380007085.XA Active CN104066719B (zh) 2012-01-31 2013-01-24 用作mogat-2抑制剂的苄基磺酰胺衍生物

Country Status (27)

Country Link
US (1) US8575352B2 (enExample)
EP (1) EP2809651B1 (enExample)
JP (1) JP2015511232A (enExample)
KR (1) KR20140106750A (enExample)
CN (1) CN104066719B (enExample)
AP (1) AP2014007794A0 (enExample)
AR (1) AR089771A1 (enExample)
AU (1) AU2013215468A1 (enExample)
BR (1) BR112014018636A8 (enExample)
CA (1) CA2859995A1 (enExample)
CL (1) CL2014001861A1 (enExample)
CO (1) CO7010839A2 (enExample)
CR (1) CR20140322A (enExample)
DO (1) DOP2014000178A (enExample)
EA (1) EA201491276A1 (enExample)
ES (1) ES2590929T3 (enExample)
GT (1) GT201400167A (enExample)
HK (1) HK1199025A1 (enExample)
IL (1) IL233712A0 (enExample)
MA (1) MA35886B1 (enExample)
MX (1) MX2014008599A (enExample)
PE (1) PE20141679A1 (enExample)
PH (1) PH12014501711A1 (enExample)
SG (1) SG11201404106QA (enExample)
TW (1) TW201343629A (enExample)
WO (1) WO2013116075A1 (enExample)
ZA (1) ZA201404836B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112323A1 (en) 2012-01-23 2013-08-01 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
WO2013116065A1 (en) 2012-01-31 2013-08-08 Eli Lilly And Company Novel morpholinyl derivatives useful as mogat-2 inhibitors
MX2015005739A (es) 2012-11-06 2015-09-16 Lilly Co Eli Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2.
DK3307262T3 (da) 2015-06-15 2021-08-09 Nmd Pharma As Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US12440477B2 (en) 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
KR20210114001A (ko) 2019-01-11 2021-09-17 시오노기 앤드 컴파니, 리미티드 Mgat2 저해 활성을 갖는 다이하이드로피라졸로피라지논 유도체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655283A1 (en) * 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
EP1659113A1 (en) * 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP2078719A1 (en) * 2006-09-28 2009-07-15 Dainippon Sumitomo Pharma Co., Ltd. Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the compound
WO2010095767A1 (en) * 2009-02-23 2010-08-26 Banyu Pharmaceutical Co.,Ltd. Pyrimidin-4(3h)-one derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006051378A1 (en) * 2004-11-10 2006-05-18 Pfizer Japan Inc. Substituted n-sulfonylaminobenzyl-2-phenoxy acetamide compounds
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物
CN101511808A (zh) * 2006-09-08 2009-08-19 辉瑞产品公司 二芳基醚衍生物及其用途
JP2010509392A (ja) * 2006-11-13 2010-03-25 ファイザー・プロダクツ・インク ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2013112323A1 (en) 2012-01-23 2013-08-01 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
WO2013116065A1 (en) 2012-01-31 2013-08-08 Eli Lilly And Company Novel morpholinyl derivatives useful as mogat-2 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655283A1 (en) * 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
EP1659113A1 (en) * 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP2078719A1 (en) * 2006-09-28 2009-07-15 Dainippon Sumitomo Pharma Co., Ltd. Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the compound
WO2010095767A1 (en) * 2009-02-23 2010-08-26 Banyu Pharmaceutical Co.,Ltd. Pyrimidin-4(3h)-one derivatives

Also Published As

Publication number Publication date
CA2859995A1 (en) 2013-08-08
EP2809651B1 (en) 2016-06-29
US8575352B2 (en) 2013-11-05
KR20140106750A (ko) 2014-09-03
BR112014018636A8 (pt) 2017-07-11
PH12014501711A1 (en) 2014-10-13
AR089771A1 (es) 2014-09-17
CL2014001861A1 (es) 2014-11-07
EA201491276A1 (ru) 2014-10-30
AU2013215468A1 (en) 2014-07-10
PE20141679A1 (es) 2014-11-08
MA35886B1 (fr) 2014-12-01
DOP2014000178A (es) 2014-08-31
HK1199025A1 (en) 2015-06-19
US20130197039A1 (en) 2013-08-01
IL233712A0 (en) 2014-09-30
BR112014018636A2 (enExample) 2017-06-20
MX2014008599A (es) 2014-08-22
ES2590929T3 (es) 2016-11-24
CN104066719A (zh) 2014-09-24
CR20140322A (es) 2014-08-25
CO7010839A2 (es) 2014-07-31
JP2015511232A (ja) 2015-04-16
TW201343629A (zh) 2013-11-01
ZA201404836B (en) 2017-08-30
EP2809651A1 (en) 2014-12-10
WO2013116075A1 (en) 2013-08-08
GT201400167A (es) 2015-05-28
AP2014007794A0 (en) 2014-07-31
SG11201404106QA (en) 2014-08-28

Similar Documents

Publication Publication Date Title
CN104066719B (zh) 用作mogat-2抑制剂的苄基磺酰胺衍生物
US9073856B2 (en) Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
UA128114C2 (uk) Тверді форми 3-((1r,3r)-1-(2,6-дифтор-4-((1-(3-фторпропіл)азетидин-3-іл)аміно)феніл)-3-метил-1,3,4,9-тетрагідро-2h-піридo[3,4-b]індол-2-іл)-2,2-дифторпропан-1-олу і способи одержання конденсованих трициклічних сполук, що містять заміщене фенільне або піридинільне угруповання, в тому числі способи їх застосування
TW201726695A (zh) （ｒ）-及（ｓ）-１-（３-（３-ｎ，ｎ-二甲基胺基羰基）苯氧基-４-硝苯基）-１-乙基-ｎ，ｎ’-雙（伸乙基）胺基磷酸酯、組合物及其使用及製備方法
CN102574860A (zh) 吡咯并[2,3-d]嘧啶化合物
CN104080777B (zh) 用作mogat-2抑制剂的吗啉基衍生物
EP4017843A1 (en) Benzenesulfonamide derivatives and uses thereof
JP2025121901A (ja) ファルネソイドｘ受容体アゴニストの結晶質形態
JP2016501844A (ja) ＭｏＧＡＴ−２阻害剤として有用な新規のベンジルスルホンアミド化合物
CN110483487B (zh) 一种2-硫甲基吡唑嘧啶酮类化合物、其制备方法、药物组合物及应用
CN112105355B (zh) Abhd12抑制剂及其制造和使用方法
WO2018085263A1 (en) Compounds for treatment of neurodegenerative diseases
JP2022115836A (ja) Ｌｐａ１受容体を拮抗するウレア化合物を有効成分として含有する医薬
JP2025521336A (ja) 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤の固体形態
JP2025539698A (ja) 新規シアノピリジンｋｈｋ阻害剤化合物
HK40087373A (zh) 氨基嘧啶基衍生物
HK1199024B (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant